Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Cancer Immunol Res. 2014 Mar 28;2(8):725–731. doi: 10.1158/2326-6066.CIR-13-0213

Figure 2.

Figure 2

Characterization of bone marrow (BM) MDSC. (a) Total number of BM CD14+ cells decreased over time when staining the Pre Tadalafil, +6 month and +11 month timepoints (b) IL4Rα (purple fill) and isotype control (green line) staining of CD14+/HLA-DRlo cells over time. IL4Rα expression showed a decrease from Pre Tadalafil, +6 months, to near normal expression at +11 months of therapy. (c) iNOS and Arg-1 expression levels relative to β-actin in Pre Tadalafil, +6 months, +11 months and a normal BM sample. (d) ROS staining of CD14+/HLA-DRlo cells at the Pre Tadalafil, +6 month and +11 month time points as well as a normal BM for comparison.